The U.S. Food and Drug Administration has approved Ixempra (ixabepilone) to treat advanced breast cancer that hasn’t responded to treatment with three other types of chemotherapy. The drug was also approved for use with Xeloda (capecitabine) in women with breast cancer that has spread to other parts of the body.
The U.S. Food and Drug Administration has approved Combigan eyedrops to slow the progression of glaucoma. The combination drug contains brimonidine tartrate (an alpha-adrenergic receptor agonist) and timolol maleate (a beta-
adrenergic receptor blocker). Combigan, which helps reduce elevated intraocular pressure in patients with glaucoma or ocular hypertension, may be used as adjunctive or replacement therapy.
Marketing of Trasylol suspended
At the request of the U.S. Food and Drug Administration, Bayer Pharmaceuticals has agreed to a marketing suspension of Trasylol (aprotinin injection), pending a review of preliminary results from a Canadian study suggesting an increased risk of death. The drug is used to control bleeding during heart surgery.